We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.67 | -2.38% | 27.49 | 28.49 | 27.40 | 28.31 | 65,588,937 | 00:59:52 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 3, 2017 (February 2, 2017)
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-3619
|
13-5315170
|
(State or other Jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
10017
(Zip Code) |
Registrant's telephone number, including area code:
(212) 733-2323
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.0 1 |
Other Events |
On February 2, 2017, Pfizer Inc. ("Pfizer") entered into an accelerated
share repurchase agreement with Citibank N.A. ("Citibank") to repurchase $5 billion of
Pfizer's common stock. Approximately 126 million of the shares to be
repurchased under the transaction will be received by Pfizer on February 6,
2017.
|
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
||
Exhibit No. | Description | |
99.1 | Press Release of Pfizer Inc. dated February 3, 2017 | |
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.
PFIZER INC.
|
||
By:
/s/ Margaret M. Madden
Margaret M. Madden |
||
Title: Vice President and Corporate Secretary
|
||
Dated: February 3, 2017 | Chief Governance Counsel |
EXHIBIT INDEX
Number |
Description |
99.1 | Press Release of Pfizer Inc. dated February 3, 2017 |
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions